BR112018001859A2 - comprimido, e, método para produzir um comprimido. - Google Patents

comprimido, e, método para produzir um comprimido.

Info

Publication number
BR112018001859A2
BR112018001859A2 BR112018001859-7A BR112018001859A BR112018001859A2 BR 112018001859 A2 BR112018001859 A2 BR 112018001859A2 BR 112018001859 A BR112018001859 A BR 112018001859A BR 112018001859 A2 BR112018001859 A2 BR 112018001859A2
Authority
BR
Brazil
Prior art keywords
tablet
competitive
outer layer
active ingredients
inner core
Prior art date
Application number
BR112018001859-7A
Other languages
English (en)
Japanese (ja)
Other versions
BR112018001859B1 (pt
Inventor
Maeda Arisa
Sugiyama Yuichi
Uchiyama Yoshihiro
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BR112018001859A2 publication Critical patent/BR112018001859A2/pt
Publication of BR112018001859B1 publication Critical patent/BR112018001859B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção fornece um comprimido em que a estabilidade dos ingredientes ativos (bloqueador de ácido de potássio competitivo e ácido acetilsalicílico) é elevada e as atividades farmacológicas dos ingredientes ativos pode ser exercida de forma estável e rápida após a administração do comprimido. a presente invenção refere-se a um comprimido com um revestimento entérico que contém um núcleo interno e uma camada externa, em que o núcleo interno contém ácido acetilsalicílico e a camada externa contém um bloqueador de ácido de potássio competitivo que não tem revestimento entérico.
BR112018001859-7A 2015-07-30 2016-07-28 Comprimido, e, método para produzir um comprimido BR112018001859B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-151336 2015-07-30
JP2015151336 2015-07-30
PCT/JP2016/072109 WO2017018473A1 (ja) 2015-07-30 2016-07-28 錠剤

Publications (2)

Publication Number Publication Date
BR112018001859A2 true BR112018001859A2 (pt) 2018-11-27
BR112018001859B1 BR112018001859B1 (pt) 2023-05-02

Family

ID=57884505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001859-7A BR112018001859B1 (pt) 2015-07-30 2016-07-28 Comprimido, e, método para produzir um comprimido

Country Status (19)

Country Link
US (1) US10835541B2 (pt)
EP (1) EP3329921B1 (pt)
JP (1) JP6778680B2 (pt)
KR (1) KR20180030412A (pt)
CN (1) CN108135915B (pt)
BR (1) BR112018001859B1 (pt)
CA (1) CA2994073C (pt)
CL (1) CL2018000246A1 (pt)
CO (1) CO2018000991A2 (pt)
CR (1) CR20180119A (pt)
EC (1) ECSP18015616A (pt)
HK (1) HK1249857A1 (pt)
MX (1) MX2018001209A (pt)
MY (1) MY189306A (pt)
PE (1) PE20180605A1 (pt)
PH (1) PH12018500236A1 (pt)
SG (2) SG11201800591TA (pt)
TW (1) TWI710379B (pt)
WO (1) WO2017018473A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000318A2 (pt) * 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CA3203701A1 (en) * 2020-12-30 2022-07-07 Min Jung Kim Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs
WO2023106841A1 (ko) 2021-12-08 2023-06-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10317023A1 (de) 2003-04-11 2004-11-11 Altana Pharma Ag Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
SA04250092B1 (ar) 2003-05-14 2008-05-04 التانا فاروا ايه جي مركب وسيط جديد لتحضير مركبات إيميدازوبيريدين imidazopyridines فعالة علاجياً
EP1682133A1 (en) 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
WO2007125397A2 (en) 2006-04-27 2007-11-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
AU2009284867B2 (en) 2008-08-27 2014-08-28 Takeda Pharmaceutical Company Limited Pyrrole compounds
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
MY162392A (en) 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
SG11201402400YA (en) 2011-11-30 2014-06-27 Takeda Pharmaceutical Dry coated tablet
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN105412038A (zh) * 2015-12-11 2016-03-23 北京阜康仁生物制药科技有限公司 一种包含沃诺拉赞和非甾体抗炎药的复方制剂

Also Published As

Publication number Publication date
JP6778680B2 (ja) 2020-11-04
CN108135915B (zh) 2021-06-25
TW201714608A (zh) 2017-05-01
EP3329921A1 (en) 2018-06-06
EP3329921A4 (en) 2019-03-27
PH12018500236A1 (en) 2018-08-13
CN108135915A (zh) 2018-06-08
CL2018000246A1 (es) 2018-06-29
HK1249857A1 (zh) 2018-11-16
WO2017018473A1 (ja) 2017-02-02
TWI710379B (zh) 2020-11-21
CA2994073A1 (en) 2017-02-02
US20180214460A1 (en) 2018-08-02
BR112018001859B1 (pt) 2023-05-02
ECSP18015616A (es) 2018-07-31
CR20180119A (es) 2018-03-21
SG11201800591TA (en) 2018-02-27
MX2018001209A (es) 2018-07-06
KR20180030412A (ko) 2018-03-22
CA2994073C (en) 2023-09-05
PE20180605A1 (es) 2018-04-09
JPWO2017018473A1 (ja) 2018-05-17
EP3329921B1 (en) 2024-03-27
MY189306A (en) 2022-02-03
CO2018000991A2 (es) 2018-05-10
SG10201914087UA (en) 2020-03-30
US10835541B2 (en) 2020-11-17

Similar Documents

Publication Publication Date Title
BR112018001859A2 (pt) comprimido, e, método para produzir um comprimido.
IL257379A (en) Diacerin or its analogs to inhibit the expression of nlrp3 and asc, and/or to create the inflammasome-nlrp3 conjugate
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
BR112016001822A2 (pt) comprimido farmacêutico compreendendo ácido acetilsalicílico e clopidogrel
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
MX2017012877A (es) Composiciones gomosas de multicomponentes con nucleo suave.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
HK1258095A1 (zh) 用於抑制il-17和其他用途的c4-改性的齊墩果酸衍生物
CL2015002148A1 (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
EA201390814A1 (ru) Перорально распадающаяся таблетка
PH12014501218B1 (en) Dry coated tablet
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
SA515361092B1 (ar) تركيبات راسكادوتريل الدهنية
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
HK1248277A1 (zh) 真正的胰腺祖細胞的分離
BR112013015382A2 (pt) bico para mamdeira com uma parede externa e uma pluralidade de recessos formada em uma parede externa e mamadeira para bebê
BR112017004948A2 (pt) formulação farmacêutica.
DK3463310T3 (da) Tabletter med højt aktivt indholdsstofindhold af omega-3-fedtsyreaminosyresalte
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
BR112018017214A2 (pt) preparação contendo esomeprazol
PH12015000297B1 (en) Pharmaceutical combination preparation
AR101728A1 (es) Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas
PT3097921T (pt) Composições que compreendem geraniol e gengibre seco para utilização no tratamento da síndrome do intestino irritável
AR113874A1 (es) Terapias de combinación de inhibidor ezh2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2730 DE 02/05/2023, QUANTO AO ITEM (54) TITULO.